Trial Profile
A Phase 3 pivotal trial PTI-428 in subjects on either Orkambi or Symdeko background therapy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Nesolicaftor (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Kineta; Proteostasis Therapeutics; Yumanity Therapeutics
- 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
- 23 Apr 2018 New trial record
- 17 Apr 2018 According to a Proteostasis Therapeutics media release, a Phase II study (see profile 700294135 ) intended to expand population of CF subjects in this trial.